Coppersmith Presentation to Alere Inc Stockholders

PAGE 9 | COPPERSMITH THE FACTS: We believe management misunderstands the effect of Alere's enormous leverage on its equity valuation and risk profile Alere's Leverage: Unsafe, Unaddressed, Unpalatable to Investors ALERE'S PLAN: 4x leverage target at the end of 2015, which in our view means waiting patiently for mediocrity COPPERSMITH'S PLAN: Aggressive portfolio rationalization to kickstart real deleveraging Divest the consumer products joint venture Fallow asset with no synergies, ignored by many in valuing the Company $240-$325mm potential proceeds Evaluate the divestiture of Toxicology Non-synergistic: Only 30% POC8; primarily sold to employers and law enforcement (i.e. not doctors and hospitals) 1. I 2. ■ ■ $2.2-$2.4B potential proceeds ▪ Potential proceeds of $700mm to $3.4B, vs. Company target of $200mm By 12/31/13 leverage would be 0.0x to 1.0x assuming a Toxicology sale and 3.7x to 4.3x assuming no Toxicology sale ■ Coppersmith's plan projects Alere at best DEBT FREE NOW and at worst TWO YEARS AHEAD of management and the Board's target

View entire presentation